You are here:

magnesium glycerophosphate (Neomag)

Advice

following an abbreviated submission:

magnesium glycerophosphate (Neomag®) is accepted for use within NHS Scotland.

Indication under review: as an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor. Magnesium glycerophosphate is also indicated for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.

Unlicensed tablet formulations of magnesium glycerophosphate have been used in the NHS in Scotland. This product provides a licensed preparation at a similar cost.

Drug Details

Drug Name: magnesium glycerophosphate (Neomag)
SMC Drug ID: 1267/17
Manufacturer: Neoceuticals Ltd
Indication: As an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor. Magnesium glycerophosphate is also indicated for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 11 September 2017

Back